Javad Ahmadian Heris

Javad Ahmadian Heris

Auto-generated profile, based on publicly available information

Javad Ahmadian Heris

Department of Allergy and Clinical Immunology, Pediatric Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2022 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
NNNarjes Nouri
Narjes Nouri
OSOlduz Shareghi-Oskoue
Olduz Shareghi-Oskoue
LAleili Aghebati-Maleki
leili Aghebati-Maleki
SDShahla Danaii
Shahla Danaii
JHJavad Ahmadian Heris
Javad Ahmadian Heris
MYMehdi Yousefi
Mehdi Yousefi
Premature ovarian failure is a to some extent unknown and intricate problem with diverse causes and clinical manifestations. The lack of ovarian sex hormones presumably is effective in the occurrence of ovarian failure. Our progress in this field has been very little despite undertaken scientific research endeavors; scholars still are trying to understand the explanation of this dilemmatic medical condition. In contrast, the practice of clinical medicine has made meaningful strides in providing assurance to the women with premature ovarian insufficiency that their quality of life as well as long-term health can be optimized through timely intervention. Very recently Scientists have investigated the regulating effects of small RNA molecules on steroidogenesis apoptosis, ovulation, gonadal, and corpus luteum development of ovaries. In this literature review, we tried to talk over the mechanisms of miRNAs in regulating gene expression after transcription in the ovary.

1 January 2023 in Reproductive Medicine and Biology
Verified
Journal Article
Open access
FPForough Parhizkar
Forough Parhizkar
MYMehdi Yousefi
Mehdi Yousefi
MSMohammad Sadegh Soltani‐Zangbar
Mohammad Sadegh Soltani‐Zangbar
ZPZahra Parhizkar
Zahra Parhizkar
LAleili Aghebati-Maleki
leili Aghebati-Maleki
JHJavad Ahmadian Heris
Javad Ahmadian Heris
Purpose: The authors developed nanostructured lipid carriers (NLCs) loaded with sirolimus (SRL) and cyclosporine (CsA) to improve their therapeutic efficacy in recurrent pregnancy loss (RPL) patients.Methods: Mono‐delivery and co‐delivery of SRL and CsA by NLCs (S‐NLCs, C‐NLCs, and S‐C‐NLCs) were developed. The MTT assay was used to study the optimum dose of formulations. PCR, Western blotting, and ELISA were also conducted.Results: Well‐designed nanodrugs with a suitable size, zeta potential, desirable encapsulation efficiency drug loading, and cellular uptake confirmed optimum formulations. Based on cell viability, the amounts of SRL and CsA could be reduced greatly due to the co‐delivery by NLCs. Following S‐NLCs and C‐NLCs interventions in T cells of patients with RPL and immune abnormality, a significant difference was observed in transcription factors and cytokine levels of Th1, Th17, and Tregs compared with healthy samples. Thus, a higher level of pro‐inflammatory cytokines (IFN‐γ, TNF‐α, IL‐17, and IL‐21) and their regulators (T‐bet and RORγt), as well as a lower level of an anti‐inflammatory cytokine (IL‐10) and its regulatory (Foxp3), were observed. However, no significant difference was found following the S‐C‐NLCs intervention.Conclusions: S‐C‐NLCs effectively balance the immune responses in peripheral T cells in RPL patients to induce maternal immune tolerance.

16 January 2025 in Journal of Reproductive Immunology
Verified
Journal Article
Closed access
MDMohsen Dashti
Mohsen Dashti
AKAmin Kamrani
Amin Kamrani
ZSZahra Shahir-Khajeh
Zahra Shahir-Khajeh
JHJavad Ahmadian Heris
Javad Ahmadian Heris
LAleili Aghebati-Maleki
leili Aghebati-Maleki
MYMehdi Yousefi
Mehdi Yousefi

8 June 2021 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Open access
SASaba Arshi
Saba Arshi
SDSepideh Darougar
Sepideh Darougar
MNMohammad Nabavi
Mohammad Nabavi
MBMohammad Hassan Bemanian
Mohammad Hassan Bemanian
MFMorteza Fallahpour
Morteza Fallahpour
NENarges Eslami
Narges Eslami
Asthmatic patients may have aspirin-exacerbated respiratory disease and experience acute dyspnea and nasal symptoms within 3 hours after the ingestion of aspirin. This study aimed to evaluate the effect and outcome of daily low-dose aspirin in the treatment of moderate to severe asthma in patients with concomitant aspirin hypersensitivity and chronic rhinosinusitis with nasal polyposis (CRSwNP). This clinical trial was conducted from February 2014 to February 2015 on 46 adult patients with moderate to severe asthma accompanied by CRSwNP. Patients with a positive aspirin challenge were blindly randomized in three groups receiving placebo/day (A); aspirin 100 mg/day (B); and aspirin 325mg/day (C), respectively. Clinical findings, FEV1 and ACT scores were recorded and compared before, during, and after treatment for 6 months (IRCT2015061521970N2). Of 46 participants at baseline, 30 patients completed this 6-month trial study. The level of asthma control was significant; based on Asthma Control Test (ACT) when comparing the results in groups A and C and also groups B and C, but it was not significant when comparing ACT scores between groups A and B. FEV1 before and after treatment was significant when comparing groups A and B, groups A and C, and groups B and C. To conclude, aspirin desensitization with a daily dose of 325 mg aspirin resulted in the improvement of long-term control of asthma. A daily aspirin dose of 100 mg was not associated with such an increase in ACT score.

29 April 2024 in Indian Journal of Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
HNHadi Nasiri
Hadi Nasiri
MYMahya Ahmadpour Youshanlui
Mahya Ahmadpour Youshanlui
ZVZahra Valedkarimi
Zahra Valedkarimi
JHJavad Ahmadian Heris
Javad Ahmadian Heris
AMAhad Mokhtarzadeh
Ahad Mokhtarzadeh
Behzad BaradaranBehzad Baradaran
Behzad Baradaran
3

2 September 2020 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Closed access
SASaba Arshi
Saba Arshi
NENarges Eslami
Narges Eslami
MNMohammad Nabavi
Mohammad Nabavi
MBMohammad Hassan Bemanian
Mohammad Hassan Bemanian
MFMorteza Fallahpour
Morteza Fallahpour
SDSepideh Darougar
Sepideh Darougar
Asthma induced by ingestion of aspirin occurs when symptoms arise within 30 minutes to three hours after aspirin consumption. Previous data indicate that sensitivity to aspirin may be associated with poorly controlled asthma. This study aims to evaluate the frequency of aspirin sensitivity in patients with moderate to severe asthma receiving conventional asthma therapy. This clinical trial was conducted on 65 patients aged 18 to 65 years with moderate to severe asthma from February 2015 to February 2016 at the Allergy Department, Hazrat-e-Rasoul Hospital, Iran University of Medical Sciences, Tehran. To assess treatment responses in patients, forced expiratory volume in the first second (FEV1) and asthma control test (ACT) scores were measured at baseline and after 3 months. The results of the oral aspirin challenge revealed a prevalence of 35.38% for sensitivity to aspirin. Hypersensitivity reactions to aspirin were detected in 60.9% of the patients with moderate asthma and 39.1% of the patients with severe asthma. All patients with positive aspirin challenge tests suffered from rhinosinusitis and in 56.5% of cases, history of previous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) was detected. No meaningful differences were found between those patients with aspirin sensitivity and those with aspirin tolerance neither in mean prebronchodilator FEV1 nor in ACT scores pre- and post-treatment. To conclude, aspirin sensitivity was not found to have an association with an unfavorable response to conventional treatment in patients with uncontrolled asthma.